atyr Pharma (ATYR) Earnings Date & Reports

Key Takeaways

• aTyr Pharma reported a net loss of $18.3 million, or $7.43 per share, for the third quarter of 2026, narrowing from a $25.7 million loss ($10.60 per share) a year earlier.
• The company recorded no revenue in the quarter, compared with $190,000 in license and collaboration revenue in the prior-year period.
• Research and development (R&D) expenses fell to $10.4 million from $22.1 million, reflecting an August 2026 restructuring focused on lead candidate efzofitimod.
• Cash, cash equivalents, restricted cash, and investments totaled $50.3 million at September 30, 2026, which management expects to fund operations into late 2028.
• aTyr reached alignment with the U.S. Food and Drug Administration (FDA) on a Phase 3 study of efzofitimod in pulmonary sarcoidosis and began study-related activities in the fourth quarter of 2026.
• The per-share figures reflect a 1-for-40 reverse stock split that took effect on October 29, 2026.
• For more context on aTyr Pharma's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• Explore Trending AI Robots to see how AI-driven strategies are navigating current market conditions.

Earnings Context and Why It Matters

aTyr Pharma is a clinical-stage biotechnology company with no commercialized products, so its quarterly earnings report functions less as a profit-and-loss statement and more as a progress report on pipeline execution and capital position. The company has undergone a dramatic transformation in 2026, including an approximately 60% workforce reduction, the termination of its Japanese collaboration with Kyorin, and leadership changes. Investors are therefore closely watching whether the leaner cost structure can sustain the development of efzofitimod, its lead drug candidate for interstitial lung disease (ILD), a group of immune-mediated disorders that cause inflammation and scarring of the lungs. The combination of shrinking expenses, a recent FDA alignment milestone, and a shrinking cash balance makes this report a pivotal checkpoint.

Reported Results

For the third quarter ended September 30, 2026, aTyr Pharma reported a net loss attributable to the company of $18.3 million, or $7.43 per share, compared with a net loss of $25.7 million, or $10.60 per share, in the same period a year earlier. Total revenue was $0, down from $190,000 in the prior-year quarter, which had included license and collaboration revenue.

Operating expenses declined to $18.8 million from $26.9 million. Within that total, R&D expenses fell to $10.4 million from $22.1 million, primarily reflecting costs for the Phase 2 EFZO-CONNECT study and preclinical candidates. By contrast, general and administrative (G&A) expenses rose to $8.3 million from $4.8 million. The company ended the quarter with $50.3 million in cash, cash equivalents, restricted cash, and available-for-sale investments, down from $80.9 million at the end of 2025.

The reported per-share loss reflects the 1-for-40 reverse stock split that took effect on October 29, 2026, which reduced the share count and should be considered when comparing figures to earlier consensus estimates.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and emerging market opportunities more efficiently than manual screening. For those following aTyr Pharma or evaluating comparable biotechnology names, the AI Screener offers a structured way to monitor evolving setups and signals.

Market Reaction and Investor Sentiment

Investor sentiment around aTyr Pharma has been shaped less by the financial figures themselves than by the company's restructuring and regulatory progress. The August 2026 workforce reduction and the termination of the Kyorin partnership pressured the stock, which has traded near its 52-week lows. However, the company's alignment with the FDA on the design of a global Phase 3 study for efzofitimod in pulmonary sarcoidosis removed a key uncertainty around the pivotal trial, and shares rose in after-hours trading following related announcements.

The reverse stock split, intended to restore compliance with Nasdaq's minimum bid price requirement, adds a mechanical layer to post-earnings price action that investors should interpret carefully. Underlying sentiment continues to hinge on the credibility of the efzofitimod program and the company's ability to fund the next stage of development.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the initiation of the global Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis and restrictive lung disease, with study-related activities underway in the fourth quarter of 2026. The trial is designed to enroll up to roughly 372 patients and will measure change in forced vital capacity (FVC), a key measure of lung function, as its primary endpoint.

Investors should also watch for full results from the Phase 2 EFZO-CONNECT study of efzofitimod in systemic sclerosis-related ILD, which aTyr expects to report in the second quarter of 2027. These data will help inform the broader clinical and commercial case for the drug.

On the financial side, the company's $50.3 million cash position is expected to fund current operations into late 2028, but management has signaled that advancing the Phase 3 program beyond initial study-related activities will depend on securing strategic partnerships or licensing arrangements. Cost discipline following the restructuring, the outcome of any partnering discussions, and continued Nasdaq listing compliance following the reverse stock split are all factors that could shape the stock's trajectory in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations